sr141716 has been researched along with Behavior Disorders in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fabisiak, A; Fabisiak, N; Fichna, J; Storr, M; Włodarczyk, M | 1 |
| Rosenson, RS | 1 |
| Bedogni, G; Chavez-Tapia, NC; Crocè, LS; Masutti, F; Tellez-Avila, FI; Tiribelli, C | 1 |
| Crippa, JA; Hallak, JE; Zuardi, AW | 1 |
| Bhatt, DL; Bousser, MG; Cohen, E; Creager, MA; Despres, JP; Easton, JD; Fox, KA; Gaudin, C; Hamm, CW; Job, B; Montalescot, G; Murphy, JH; Pearson, TA; Steg, PG; Topol, EJ | 1 |
| Buggy, Y; Egberts, TC; Layton, D; Leufkens, HG; Mantel-Teeuwisse, AK; Straus, SM; Willemen, MJ | 1 |
4 review(s) available for sr141716 and Behavior Disorders
| Article | Year |
|---|---|
Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis.
Topics: Amides; Cannabinoid Receptor Antagonists; Constipation; Gastrointestinal Agents; Gastrointestinal Diseases; Humans; Irritable Bowel Syndrome; Mental Disorders; Pyridines; Rimonabant | 2019 |
Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk.
Topics: Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Clinical Trials as Topic; Endocannabinoids; Humans; Mental Disorders; Obesity, Abdominal; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors | 2009 |
Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.
Topics: Cannabinoid Receptor Antagonists; Fatty Liver; Humans; Mental Disorders; Nervous System Diseases; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Treatment Outcome | 2009 |
[Therapeutical use of the cannabinoids in psychiatry].
Topics: Animals; Cannabidiol; Dronabinol; Humans; Mental Disorders; Piperidines; Psychotropic Drugs; Pyrazoles; Rimonabant | 2010 |
1 trial(s) available for sr141716 and Behavior Disorders
| Article | Year |
|---|---|
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Double-Blind Method; Drug Approval; Female; Gastrointestinal Diseases; Humans; Male; Mental Disorders; Obesity; Piperidines; Pyrazoles; Rimonabant; Suicide | 2010 |
2 other study(ies) available for sr141716 and Behavior Disorders
| Article | Year |
|---|---|
Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring study.
Topics: Adult; Body Mass Index; Cannabinoid Receptor Antagonists; Cohort Studies; Drug Monitoring; Drug Prescriptions; Female; Humans; Male; Mental Disorders; Middle Aged; Obesity; Patient Compliance; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Substance Withdrawal Syndrome; Time Factors | 2012 |
[Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Cannabinoids; Central Nervous System; Central Nervous System Diseases; Drug Approval; Germany; Humans; Mental Disorders; Metabolic Syndrome; Piperidines; Pyrazoles; Rimonabant; United States; United States Food and Drug Administration; Weight Loss | 2007 |